Literature DB >> 20116155

Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study.

Ming-Nan Lai1, Jung-Nien Lai, Pau-Chung Chen, Shu-Ching Hsieh, Fu-Chang Hu, Jung-Der Wang.   

Abstract

BACKGROUND: Taiwan has a remarkably high incidence of end-stage renal disease (ESRD). The objective of this study is to determine the association between prescribed herbal products containing aristolochic acid and ESRD. STUDY
DESIGN: Population-based case-control study. SETTING & PARTICIPANTS: All new ESRD cases in Taiwan and a simple random sample (200,000 people) drawn from the national health insurance reimbursement database in 1997-2002. PREDICTOR: Age; sex; hypertension; diabetes; cumulative doses of nonsteroidal anti-inflammatory drugs, acetaminophen, and adulterated herbal supplements potentially containing aristolochic acid before the development of chronic kidney disease; and indications for prescribing such herbs, including chronic hepatitis, chronic urinary tract infection, chronic neuralgia, or chronic musculoskeletal diseases. OUTCOMES & MEASUREMENTS: Occurrence of ESRD through construction of multiple logistic regression models.
RESULTS: There were 36,620 new ESRD cases from 1998 through 2002. After exclusion of cases with chronic kidney disease diagnosed before July 1, 1997, there were 25,843 new cases of ESRD and 184,851 controls in the final analysis. Women, older age, hypertension, and diabetes were significantly associated with increased risks of the development of ESRD. After adjustment for known risk factors, cumulative doses >60 g of Mu Tong (OR, 1.47 [95% CI, 1.01-2.14] for 61-100 g; OR, 5.82 [95% CI, 3.89-8.71] for >200 g) or Fangchi (OR, 1.60 [95% CI, 1.20-2.14] for 61-100 g; OR, 1.94 [95% CI, 1.29-2.92] for >200 g) were associated with increased risk of the development of ESRD with a dose-response relationship. This relationship persisted when analyses were limited to participants who consumed <500 pills of nonsteroidal anti-inflammatory drugs and those without diabetes. LIMITATIONS: No measurement of renal function, no contact with patients, over-the-counter sales were not recorded, and potential underestimation of exposure dose for cases and ORs.
CONCLUSIONS: Consumption of >60 g of Mu Tong or Fangchi from herbal supplements was associated with an increased risk of developing kidney failure. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20116155     DOI: 10.1053/j.ajkd.2009.10.055

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  31 in total

1.  Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1.

Authors:  Wei Li; Hong Jiang; Jiang-Min Feng
Journal:  Mol Cell Biochem       Date:  2012-06-04       Impact factor: 3.396

Review 2.  Phytochemicals in the oncology setting.

Authors:  Catherine E Ulbricht; Wendy Chao
Journal:  Curr Treat Options Oncol       Date:  2010-12

3.  [Acute tubulointerstitial nephritis as hyperergic reaction of the kidneys].

Authors:  A Schwarz; J U Becker; H Haller
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

4.  Aristolochic acid-associated urothelial cancer in Taiwan.

Authors:  Chung-Hsin Chen; Kathleen G Dickman; Masaaki Moriya; Jiri Zavadil; Viktoriya S Sidorenko; Karen L Edwards; Dmitri V Gnatenko; Lin Wu; Robert J Turesky; Xue-Ru Wu; Yeong-Shiau Pu; Arthur P Grollman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

5.  Is Duhuo Jisheng Tang containing Xixin safe? A four-week safety study.

Authors:  Shu-Ching Hsieh; Jung-Nien Lai; Pau-Chung Chen; Chao-Chung Chen; Huey-Jen Chen; Jung-Der Wang
Journal:  Chin Med       Date:  2010-02-11       Impact factor: 5.455

6.  New Approaches for Biomonitoring Exposure to the Human Carcinogen Aristolochic Acid.

Authors:  Byeong Hwa Yun; Viktoriya S Sidorenko; Thomas A Rosenquist; Kathleen G Dickman; Arthur P Grollman; Robert J Turesky
Journal:  Toxicol Res (Camb)       Date:  2015-07-01       Impact factor: 3.524

7.  Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease.

Authors:  Ming-Yen Lin; Yi-Wen Chiu; Jung-San Chang; Hung-Lung Lin; Charles Tzu-Chi Lee; Guei-Fen Chiu; Mei-Chuan Kuo; Ming-Tsang Wu; Hung-Chun Chen; Shang-Jyh Hwang
Journal:  Kidney Int       Date:  2015-08-05       Impact factor: 10.612

Review 8.  Risk assessment of upper tract urothelial carcinoma related to aristolochic acid.

Authors:  Felicia Wu; Tianxiu Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

9.  Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan.

Authors:  Tze-Wah Kao; Yu-Yin Chang; Pau-Chung Chen; Chih-Cheng Hsu; Yu-Kang Chang; Yu-Hung Chang; Lukas Jyuhn-Hsiarn Lee; Kwan-Dun Wu; Tun-Jun Tsai; Jung-Der Wang
Journal:  Perit Dial Int       Date:  2013-05-01       Impact factor: 1.756

10.  Factors associated with CKD in the elderly and nonelderly population.

Authors:  Ming-Yen Lin; Yi-Wen Chiu; Chien-Hung Lee; Hui-Yen Yu; Hung-Chun Chen; Ming-Tsang Wu; Shang-Jyh Hwang
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.